de Waal R M, Cornelissen I M, Capel P J, Koene R A
J Immunol. 1979 Sep;123(3):1353-5.
Enhancement of growth of a B10.D2 fibrosarcoma in B6AF1 recipients could be induced by administration of B6AF1 anti-B10.D2 lymphocyte serum. The role of the Fc part in this phenomenon was studied by treatment of the B6AF1 recipients with F(ab')2 fragments of enhancing alloantibodies. A highly purified F(ab')2 preparation was used to exclude any effects of undigested IgG. Administration of F(ab')2 did not lead to enhancement of the tumor allografts, not even when given in a dose that was 22 times the molar amount of the lowest enhancing dose of undigested IgG. We therefore conclude that passive enhancement of mouse tumor allografts by alloantibodies is Fc dependent.
给B6AF1受体注射B6AF1抗B10.D2淋巴细胞血清可诱导B10.D2纤维肉瘤在B6AF1受体中的生长增强。通过用增强同种抗体的F(ab')2片段处理B6AF1受体，研究了Fc部分在此现象中的作用。使用高度纯化的F(ab')2制剂以排除未消化IgG的任何影响。给予F(ab')2不会导致肿瘤同种异体移植的增强，即使给予的剂量是未消化IgG最低增强剂量摩尔量的22倍时也不会。因此，我们得出结论，同种抗体对小鼠肿瘤同种异体移植的被动增强是Fc依赖性的。
